Impaired Microcirculation in Children After Kidney Transplantation: Everolimus Versus Mycophenolate Based Immunosuppression Regimen

Kidney Blood Press Res. 2018;43(3):793-806. doi: 10.1159/000489915. Epub 2018 May 22.

Abstract

Background/aims: Whether the immunosuppressive regimen is associated with micro- and macro-vascular status in pediatric kidney transplant recipients (KTx) is unknown.

Methods: We performed a cross-sectional, case-control study in 44 pediatric KTx patients on either everolimus (EVR) plus calcineurin inhibitor or standard treatment, i.e. mycophenolate mofetil plus calcineurin inhibitor. Measurement of carotid intima-media thickness (cIMT) via ultrasound, central pulse wave velocity (PWV) by a cuff-based oscillometric technique, and skin microvascular blood flow during local heating via laser-Doppler-fluximetry (LDF) served as marker of subclinical vascular disease. Serum concentrations of angiopoietin-1 and -2, fibroblast-growth factor 23 (FGF23) and soluble klotho were measured.

Results: EVR-treated patients exhibited a similar degree of hypertension, increased cIMT, elevated pro-inflammatory angiopoietin-2, and diminished endothelial survival factor angiopoietin-1 compared to healthy children but presented with a twofold more reduced skin micro-vascular function compared to standard treatment (each p< 0.001). By contrast, PWV and soluble klotho levels were normal in both groups.

Conclusion: Endothelial dysfunction seems more frequent in KTx patients on EVR-based immunosuppressive regimen compared to standard immunosuppression.

Keywords: Atherosclerosis; Children; Endothelial dysfunction; Everolimus; Kidney transplantation; Skin microcirculation.

MeSH terms

  • Adolescent
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Cross-Sectional Studies
  • Endothelium / physiopathology
  • Everolimus / pharmacology
  • Everolimus / therapeutic use
  • Fibroblast Growth Factor-23
  • Humans
  • Immunosuppressive Agents / pharmacology*
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation / adverse effects*
  • Microcirculation / drug effects*
  • Mycophenolic Acid / pharmacology
  • Mycophenolic Acid / therapeutic use
  • Vascular Diseases / diagnosis

Substances

  • FGF23 protein, human
  • Immunosuppressive Agents
  • Fibroblast Growth Factor-23
  • Everolimus
  • Mycophenolic Acid